Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEMIRA: Tocilizumab Maintenance with/without Glucocorticoid Discontinuation
NCT02573012Phase 4Completed
- Sponsor
- Roche
- Start
- Mar 2016
- Primary completion
- Feb 2018
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 6
01
Overview
A Phase 4 trial of tocilizumab in rheumatoid arthritis (RA), sponsored by Roche. Started Mar 2016; status: completed.
02
Drugs
tocilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02573012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02573012.